InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) Takes Off Again

Yesterday, InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) stock prices jumped another 12.25% on the news that the company has received FDA approval to broaden inclusion criteria and increase the number of testing sites for its research to a total of 20.

This is indeed excellent news, as broadening the eligibility criteria of NVIV‘s test subjects and increasing the number of test sites will speed up the research process immensely. Increasing the age range from 55 to 65, expanding spinal cord injury level from T3-T11 to T3-T12/L1, extending the enrollment window from 10 to 21 days post injury, and increasing Body Mass Index upper limit of subjects from 35 to 39 will allow for more extensive testing and analysis to take place at once.

It should be obvious why such news almost pushed NVIV beyond the $1 mark. Still, although the company’s outlook may be good, investors would do well to remember that NVIV is still in the beginning stages of clinical trials. So far, it has just one test subject. Evidently the FDA has faith in NVIV‘s work, or otherwise it wouldn’t be assisting the company so actively – but even so, it would take a tremendous amount of research for NVIV to be able to present a finished product, even if its science checks out.

So the good news is that the company is moving forward at a steady pace. The not so good news is that it still has a long, long way to go.